STOCK TITAN

Theralase Techs (TLTFF) Stock News, Nov 2020-Jun 2021

TLTFF OTC

Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.

Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.

Rhea-AI Summary

Theralase Technologies Inc. (OTCQB: TLTFF) has announced the opening of a new clinical study site at UChicago Medicine for its pivotal Phase II study targeting non-muscle invasive bladder cancer (NMIBC). The study will treat approximately 100-125 patients unresponsive to BCG therapy. UChicago Medicine received IRB approval and has begun patient enrollment. To date, 23 patients have been treated, including those from an earlier phase. The company aims to submit data for Breakthrough Designation to the FDA after treating the first 25 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Theralase Technologies, a clinical stage pharmaceutical company, released its 2020 audited financials, showing a 4% decline in total revenue to $929,122 due to the pandemic's impact on healthcare purchases. Cost of sales fell by 27%, improving gross margin to 29%. Operating expenses decreased by 21%, resulting in a net loss of $5,598,540, down 24% from 2019. Significant highlights include FDA Fast Track designation for their NMIBC treatment and ongoing COVID-19 research efforts. The company is collaborating with PHAC on a COVID-19 vaccine project.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.00%
Tags
none
-
Rhea-AI Summary

Theralase Technologies has released its Quarterly Newsletter detailing progress in its Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study. The report highlights the launch of 11 Clinical Study Sites across Canada and the US, with 21 patients treated to date. Preliminary results show a Complete Response (CR) rate of 33.3% at 90 days and 28.6% at 180 days, with a total response rate of 42.8% and 38.1% respectively. Importantly, patient safety assessments indicate adverse events unrelated to the study drug.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
Rhea-AI Summary

Theralase Technologies Inc. has announced a Collaborative Research Agreement (CRA) with the National Microbiology Laboratory of Canada for the development of a COVID-19 vaccine. The partnership aims to utilize Theralase's patented Photo Dynamic Compounds (PDCs) and proprietary light technology to inactivate the SARS-CoV-2 virus and create vaccine building blocks. The project, named 'Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine', is set to start in mid-April 2021. Theralase's collaboration with PHAC leverages their expertise in vaccine development and aims to advance research in anti-viral solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.00%
Tags
none
-
Rhea-AI Summary

Theralase Technologies Inc. (TLTFF) announced the launch of its Anti-Cancer Therapy (ACT) research centre at the Li Ka Shing Knowledge Institute, effective April 1, 2022. This move, which relocates the research team from the University Health Network, aims to accelerate the development and commercialization of its lead Photo Dynamic Compound, TLD-1433, and its formulation Rutherrin. The centre will enhance collaboration and access to expertise, facilitating advancements in Theralase's pivotal Phase II Non-Muscle Invasive Bladder Cancer clinical study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Theralase Technologies Inc. has received Institutional Review Board approval for its Phase II Clinical Study targeting Non-Muscle Invasive Bladder Cancer (NMIBC) at Urology San Antonio. This site marks the sixth US clinical study site to obtain such approval. Currently, 16 patients are involved in the study, with a target of 25 patients for potential Breakthrough Designation. CEO Shawn Shirazi expressed enthusiasm over meeting clinical site targets and the prospect of expanding patient enrollment in early 2021. Additional sites are anticipated to launch in Q2 and Q3 of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
Rhea-AI Summary

Theralase Technologies Inc. (TSXV:TLT, OTCQB:TLTFF) announced that the University of Wisconsin Health-Madison received IRB approval for a pivotal Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study. This study targets patients with BCG-Unresponsive Carcinoma In-Situ. The approval marks the fifth clinical site in the US for this study, with another pending. Theralase aims to treat 25 patients in 2021 to seek Breakthrough Designation Approval, with 75-100 additional patients planned for 2021/2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
-
Rhea-AI Summary

Theralase Technologies has received ethics approval from University of British Columbia to initiate a Pivotal Phase II clinical study targeting Non-Muscle Invasive Bladder Cancer (NMIBC). This study will enroll approximately 100 patients who are BCG-Unresponsive or intolerant to BCG Therapy. Currently, 14 patients have been treated across 5 clinical sites in Canada. FDA Fast Track Designation may expedite drug-device development. The primary endpoint focuses on the efficacy defined by Complete Response (CR).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary

Theralase Technologies Inc. (TLTFF) reported its 3Q2020 financial results, showing a slight revenue decline of 2% compared to the previous year, with total revenue of $514,891. The company faced challenges due to the COVID-19 pandemic, which impacted sales and operations. Gross margin remained stable at 27%, while operating expenses increased by 7%, leading to a net loss of $4,399,045, representing a 7% rise from the prior year. Notably, the FDA granted Fast Track Designation for Study II, enabling accelerated communication with regulators and potential approval pathways for its treatment of non-muscle invasive bladder cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
Rhea-AI Summary

Theralase Technologies Inc. (TSXV:TLT, OTCQB:TLTFF) announced that the FDA has granted its TLD-1433 drug candidate Fast Track Designation for the Phase II study targeting BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). This designation will enhance communication with the FDA, potentially accelerating the approval process. The Phase II study aims to treat 100 patients across 20 sites in Canada and the US, focusing on safety and efficacy metrics. This recognition underscores Theralase's commitment to improving patient outcomes for this serious health condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.00%
Tags

FAQ

What is the current stock price of Theralase Techs (TLTFF)?

Theralase Techs (TLTFF) last closed at $0.1162.

What is the market cap of Theralase Techs (TLTFF)?

The market cap of Theralase Techs (TLTFF) is approximately $36.1M.